BullFrog AI Strengthens Capabilities of its AI Platform Through Expansion of Licensing Agreement with Johns Hopkins Applied Physics Laboratory

BullFrog AI Holdings,a digital technology company using machine learning to usher in a new era of precision medicine, announced the expansion of its worldwide license agreement with the Johns Hopkins Applied Physics Laboratory (APL), in Laurel, Maryland, for use of patented technology powering the Company’s bfLEAP platform, an AI-driven platform for analyzing drug development data to potentially make life-saving therapies and treatments available to patients more quickly.

Recommended: AiThority Interview with Arijit Sengupta, CEO and Founder at Aible

“We are committed to firmly establishing BullFrog AI as the undisputed leader in artificial intelligence-driven drug development,” said Vin Singh, Founder and CEO of BullFrog AI. “Our expanded license with APL is a testament to our relentless pursuit of innovation, enabling us to harness the full potential of AI in accelerating the development of life-saving therapies. This breakthrough technology not only has the potential to disrupt the industry, but also transform countless lives across the globe.”

The patented technology from APL powering bfLEAP includes analytical models that enable the analysis and interpretation of large, complex, and diverse datasets that may be incomplete and comprise both numerical and categorical data and provide explainable results. The innovative technology, which enables the detection of anomalies, patterns, and relationships, has been shown to perform better than well-known algorithms in benchmarking tests.

The latest APL license improvements enable bfLEAP capabilities to be much more robust, both from a software perspective and mathematically. Additionally, the introduction of multivariate diffuse indexing, a new algorithm for analysis of mixed categorical/numerical data that supports both link inference and probabilistic modeling, allows probabilistic models to work with mixed data without any additional transformation.

Recommended: Embrace AI to become a W.I.T.C.H. Leader

Furthermore, the creation of a new repository that now houses all of the graph algorithms has led to a more organized structure with three equivalent-sized repositories containing around 80 runnable analytics each. This update brings numerous robustness and usability improvements to the platform.

BullFrog AI is deploying bfLEAP for use at several critical stages of therapeutics development with the intention of streamlining data analytics, decreasing the overall development costs by decreasing failure rates for new therapeutics and impacting the lives of countless patients that may otherwise not receive the therapies they need.

Top AI ML Insights: AiThority Interview with Alex Mans, Founder and CEO at FLYR Lab

[To share your insights with us, please write to sghosh@martechseries.com]

The post BullFrog AI Strengthens Capabilities of its AI Platform Through Expansion of Licensing Agreement with Johns Hopkins Applied Physics Laboratory appeared first on AiThority.

therapeutics
artificial intelligence
ai
machine learning
data analytics
software
medicine